What Got You Interested in
Epilepsy Research?
I have always been fascinated by the clinical spectrum of epileptic disorders and the impact that the unpredictability of epileptic seizures has on many aspects of a patient's life. During my residency, epilepsy was still mostly seen as an "ion channel disorder," supported by the fact that most antiepileptic drugs target ion channels. Nevertheless, work as a resident in an academic epilepsy center made it soon clear that many patients with epilepsy do not respond to even a mix of several antiepileptic drugs. To me, this seemed to reflect that we did not yet fully understand the underlying pathogenic mechanisms of epilepsy. During my second year of residency, I was given the opportunity to search for (and identify) the genetic cause (an ATP1A2 mutation) of a large Belgian family with epilepsy and hemiplegic migraine, in collaboration with the group of Prof. De Jonghe. This project instigated my interest in genetics, and fueled the belief that genetics is a powerful tool to decipher the biology of epilepsy.
Explain for Our General Readership What Question Your
Study Addressed and How Did You Go About Designing Your Study?
Activation of the mammalian target of rapamycin (mTOR) pathway has long been known to play a major role in tuberous sclerosis, in which epilepsy is often part of the clinical More recently, loss-of-function mutations in the gene DEPDC5, which inhibits the mTOR complex 1 (mTORC1), were shown to lead to familial focal epilepsy with or without focal cortical dysplasia. In our study, we aimed to study the contribution of mutations in genes encoding proteins that form a complex or interact with DEPDC5, the GATOR1 and GATOR2 complex genes, to the etiology of focal epilepsies, and to describe the associated phenotypical spectrum. We therefore performed targeted sequencing of the GATOR1 and GATOR2 complex genes in a cohort of 93 European probands with focal epilepsy with or without focal cortical dysplasia. We also validated mTORC1 activation using phospho-S6 immunoreactivity in resected brain tissue of patients carrying pathogenic variants.
What Were the Results and How Do You Interpret Your Findings?
We identified mutations in the GATOR1 complex genes DEPDC5, NPRL2, and NPRL3 in 11% of our cohort. All were loss-of-function variants, and we showed indeed a hyperactivation of mTORC1 in resected brain tissue from patients with NPRL2 and NPRL3 mutations who underwent epilepsy surgery. The phenotypic spectrum of patients with mutations in any of these three GATOR1 complex genes was remarkably similar, including onset of epilepsy in variable foci in larger affected families. Moreover, within families, the phenotype of mutation carriers includes unaffected individuals, people with focal epilepsy without obvious structural abnormalities, and patients with focal epilepsy and focal cortical dysplasia. These features distinguish them from families with focal epilepsy due to mutations in nonmTOR pathway genes (like KCNT1, LGI1, and the acetylcholine receptor genes). Overall, the study emphasizes the importance of GATOR1 complex genes in the etiology of more common epilepsy syndromes, and is an incentive for the evaluation of mTOR inhibitors as a targeted therapy for these entities.
What Next Steps in Epilepsy Research are You Taking and What are Your Career Goals?
These are very exciting times for epilepsy genetics. In our lab, we continue to focus on gene discovery in epilepsy, both through local next-generation sequencing studies on the most promising families, and through exciting larger initiatives as the worldwide Epi25 Collaborative, which will generate 12,000 exomes with the help of the Broad Institute and the National Human Genome Research Institute. In parallel, I would like to direct our lab's work toward an even more translational aspect of epilepsy genetics research, namely the development of targeted treatments for (neurodevelopmental) epilepsies. The combined recent advances in sequencing techniques and gene editing tools open up whole new perspectives for neuroscience research. Just as our lab has contributed to the shaping of the epilepsy genetics landscape in the last two decades, I hope to be doing the same for the next step, which is turning our increased genetic knowledge into better treatment strategies for patients.
What Does the Epilepsy Prize Mean for You, Your Laboratory, Research Institute, and Your Future?
I am extremely honored to receive this award. It is a great incentive to continue my research efforts and keep aiming for clinically meaningful results. There are moments when combining clinical work with research is challenging, but this prize from a renowned journal targeting both clinicians and researchers certainly gives an inspiring boost. The prize also recognizes the hard work of all my collaborators in the lab and my institute, and I thank them all. The prize will help me to develop my research career further, by illustrating my research capacities when searching for funding opportunities.
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